BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.700
+0.050 (3.03%)
Dec 5, 2024, 4:00 PM EST - Market closed
BeyondSpring Employees
BeyondSpring had 36 employees as of December 31, 2023. The number of employees decreased by 37 or -50.68% compared to the previous year.
Employees
36
Change (1Y)
-37
Growth (1Y)
-50.68%
Revenue / Employee
$52,111
Profits / Employee
-$432,444
Market Cap
68.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
InterCure | 270 |
Metagenomi | 236 |
Hyperfine | 131 |
Mural Oncology | 117 |
Modular Medical | 40 |
Oncolytics Biotech | 29 |
Iterum Therapeutics | 14 |
BYSI News
- 24 days ago - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting - GlobeNewsWire
- 2 months ago - BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus
- 2 months ago - BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - GlobeNewsWire
- 2 months ago - BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - GlobeNewsWire
- 3 months ago - BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - GlobeNewsWire
- 4 months ago - SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - GlobeNewsWire
- 7 months ago - BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire
- 7 months ago - BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire